Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
5(71.4%)
Phase 1
2(28.6%)
7Total
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06306339Phase 2Not Yet Recruiting

A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)

Role: lead

NCT04817202Phase 1Completed

Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)

Role: lead

NCT04679350Phase 2Terminated

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

Role: lead

NCT04679415Phase 2Completed

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

Role: lead

NCT05808335Phase 2Unknown

A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug)

Role: lead

NCT04676971Phase 2Completed

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

Role: lead

NCT03653208Phase 1Completed

Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers

Role: lead

All 7 trials loaded